|
Status |
Public on Apr 17, 2014 |
Title |
LNCaPEV_pre F |
Sample type |
RNA |
|
|
Source name |
LNCaP cells with EV control
|
Organism |
Homo sapiens |
Characteristics |
cell line: LNCaP expression: vector control
|
Treatment protocol |
No treatment
|
Growth protocol |
LNCaP cells grown in RPMI & 10% FBS
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was extracted using the QIAGEN AllPrep kit in accordance with the prescribed protocol provided with the kit. Quality control was performed with Agilent Bioanalyser.
|
Label |
biotin
|
Label protocol |
Biotinylated cRNA were prepared with the Ambion MessageAmp kit for Illumina arrays
|
|
|
Hybridization protocol |
Standard Illumina hybridization protocol
|
Scan protocol |
Standard Illumina scanning protocol
|
Description |
F
|
Data processing |
The bead-level data were preprocessed using BASH (Cairns et al. (2008) Bioinformatics 24(24):2921-2), a function from the beadarray package (Dunning et al (2007) Bioinformatics 23(16):2183-4) in Bioconductor, and also log base 2 transformed and quantile normalised using the beadarray package.
|
|
|
Submission date |
Mar 12, 2012 |
Last update date |
Apr 17, 2014 |
Contact name |
Roslin Russell |
E-mail(s) |
roslin.russell@cruk.cam.ac.uk
|
Phone |
01223 769770
|
Organization name |
Cambridge Research Institute, Cancer Research UK
|
Street address |
Robinson Way
|
City |
Cambridge |
ZIP/Postal code |
CB2 0RE |
Country |
United Kingdom |
|
|
Platform ID |
GPL6947 |
Series (2) |
GSE36434 |
Hes6 expression is controlled by c-Myc and the AR to promote E2F1 activity and poor outcome in castrate-resistant prostate cancer (LNCaP) |
GSE36526 |
Hes6 drives a network with therapeutic potential in castrate-resistant prostate cancer |
|